Vera Therapeutics will present at the J.P. Morgan Healthcare Conference, discussing immunological disease treatments.
Quiver AI Summary
Vera Therapeutics, Inc., a late clinical-stage biotechnology company focused on treatments for serious immunological diseases, announced that its management will present at the 43rd Annual J.P. Morgan Healthcare Conference from January 12-16, 2025, in San Francisco. The presentation is scheduled for January 13 at 4:30 PM PST, with a webcast available for viewing. Vera is developing innovative therapies, including atacicept, which targets autoimmune diseases by blocking factors that contribute to the production of harmful autoantibodies. Additionally, the company is working on MAU868, aimed at neutralizing BK virus infections, particularly in kidney transplant patients. Vera holds all global rights to these developmental candidates. For more information, interested parties can visit their website or contact their investor and media representatives.
Potential Positives
- Vera Therapeutics is participating in the prestigious 43rd Annual J.P. Morgan Healthcare Conference, showcasing its commitment to engaging with investors and industry leaders.
- The presentation of its lead product candidate, atacicept, at the conference highlights the company's focus on innovative treatments for serious immunological diseases.
- Vera's management will hold one-on-one investor meetings, providing opportunities to strengthen relationships with potential investors and stakeholders.
- The company retains all global developmental and commercial rights to its key therapies, indicating a strong position for potential financial gains from their products.
Potential Negatives
- Vera Therapeutics is still described as a "late clinical-stage" company, indicating challenges in progressing its drug candidates to market.
- The press release lacks significant new data on the progress or success of their lead product candidate, atacicept, which may raise concerns about transparency and confidence in its development.
- The company did not announce any major partnerships or collaborations, which could be a negative sign regarding their ability to move forward in a competitive market.
FAQ
What is the date and time of Vera Therapeutics' presentation?
The presentation will take place on January 13, 2025, at 4:30 PM PST.
Where will the J.P. Morgan Healthcare Conference be held?
The conference will be held in San Francisco, CA, from January 12 to 16, 2025.
How can I access the webcast of the event?
The webcast can be accessed at https://jpmorgan.metameetings.net/events/healthcare25.
What is Vera Therapeutics' lead product candidate?
Vera's lead product candidate is atacicept, a treatment for autoimmune diseases.
Who should I contact for media inquiries about Vera Therapeutics?
For media inquiries, contact Madelin Hawtin at LifeSci Communications.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$VERA Insider Trading Activity
$VERA insiders have traded $VERA stock on the open market 53 times in the past 6 months. Of those trades, 0 have been purchases and 53 have been sales.
Here’s a breakdown of recent trading of $VERA stock by insiders over the last 6 months:
- MARSHALL FORDYCE (PRESIDENT AND CEO) has traded it 48 times. They made 0 purchases and 48 sales, selling 219,166 shares.
- BETH C SEIDENBERG has traded it 5 times. They made 0 purchases and 5 sales, selling 31,476 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$VERA Hedge Fund Activity
We have seen 91 institutional investors add shares of $VERA stock to their portfolio, and 74 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARADIGM BIOCAPITAL ADVISORS LP added 1,096,851 shares (+inf%) to their portfolio in Q3 2024
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 984,001 shares (+inf%) to their portfolio in Q3 2024
- ARTAL GROUP S.A. removed 915,974 shares (-100.0%) from their portfolio in Q3 2024
- READYSTATE ASSET MANAGEMENT LP removed 724,992 shares (-93.8%) from their portfolio in Q3 2024
- POLAR CAPITAL HOLDINGS PLC removed 675,000 shares (-100.0%) from their portfolio in Q3 2024
- LOGOS GLOBAL MANAGEMENT LP removed 450,000 shares (-47.4%) from their portfolio in Q3 2024
- VOLORIDGE INVESTMENT MANAGEMENT, LLC removed 367,698 shares (-83.4%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12 – 16, 2025. The management team will also participate in one-on-one investor meetings.
Presentation Details:
Date: Monday, January 13, 2025
Time: 4:30 PM PST
Webcast:
https://jpmorgan.metameetings.net/events/healthcare25
A replay of the event will be available for 90 days and can be accessed by visiting the “
Investor Calendar
” section of the Vera Therapeutics website.
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit
www.veratx.com
.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
